Drugmaker AbbVie Inc. has inked a deal with Chinese drug developer I-Mab to collaborate on a cancer treatment. The deal could be worth a value of over $2.9 billion and gives Illinois-based AbbVie an exclusive global license to develop and sell I-Mab’s cancer-fighting drug lemzoparlimab outside of Greater China. Lemzoparlimab, also known as TJC4, is … Continue reading “AbbVie Inc. Signs $2.9 Billion Deal with China’s I-Mab”
Tag: AbbVie Inc.
Biotech & Pharma
Innovus Pharmaceuticals (OTC: INNV) Grows Balls With Testosterone Supplement Acquisition
Innovus Pharmaceuticals got a dose of testosterone in its share price this week. The over-the-counter…
May 24, 2016